Literature DB >> 17880834

How to choose the initial drug treatment for overactive bladder.

Scott A MacDiarmid1.   

Abstract

Antimuscarinics are the treatment of choice for patients suffering from overactive bladder syndrome (OAB). Clinical experience and the literature support the efficacy, tolerability, and safety of each agent. With increasing data and educational and marketing efforts, many health care providers are uncertain which antimuscarinic should be prescribed first. It is important to recognize that there is not one superior agent, and that the individual response to each antimuscarinic is highly variable. This paper uses peer-reviewed literature to elucidate various agents with respect to efficacy, tolerability, and safety, to help readers understand the pros and cons associated with each drug so they may better manage patients with OAB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880834     DOI: 10.1007/s11934-007-0032-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  28 in total

1.  Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice.

Authors:  Stephan G Anagnostaras; Geoffrey G Murphy; Susan E Hamilton; Scott L Mitchell; Nancy P Rahnama; Neil M Nathanson; Alcino J Silva
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

Review 2.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

3.  A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.

Authors:  C R Chapple; R Martinez-Garcia; L Selvaggi; P Toozs-Hobson; W Warnack; T Drogendijk; D M Wright; J Bolodeoku
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

4.  Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Authors:  P Van Kerrebroeck; K Kreder; U Jonas; N Zinner; A Wein
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

5.  Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies.

Authors:  Scott A MacDiarmid; Rodney U Anderson; Robert B Armstrong; Roger R Dmochowski
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

6.  Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.

Authors:  D M Gleason; J Susset; C White; D R Munoz; P K Sand
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

7.  Assessment of cognitive function of the elderly population: effects of darifenacin.

Authors:  Richard B Lipton; Ken Kolodner; Keith Wesnes
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

8.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

9.  Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.

Authors:  Margie O'Leary; Janet R Erickson; Christopher P Smith; Charlotte McDermott; John Horton; Michael B Chancellor
Journal:  J Spinal Cord Med       Date:  2003       Impact factor: 1.985

10.  Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder.

Authors:  David R Staskin; Mark D Harnett
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 3.092

View more
  4 in total

1.  Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study.

Authors:  Se Jin Park; Ki Soo Pai; Jun Mo Kim; Kwanjin Park; Kun Suk Kim; Sang Hoon Song; Sungchan Park; Sun-Ouck Kim; Dong Soo Ryu; Minki Baek; Sang Don Lee; Jung Won Lee; Young Jae Im; Sang Won Han; Jae Min Chung; Min Hyun Cho; Tae-Sun Ha; Won Yeol Cho; Hong Jin Suh
Journal:  J Korean Med Sci       Date:  2014-11-04       Impact factor: 2.153

2.  Algorithms for the management of overactive bladder.

Authors:  Richard T Kershen
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

3.  Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder.

Authors:  Franklin Chu; Neila Smith; Takeshi Uchida
Journal:  Curr Ther Res Clin Exp       Date:  2009-12

4.  Overactive bladder, differential diagnosis, and clinical utility of fesoterodine.

Authors:  Jean-Jacques Wyndaele
Journal:  Int J Gen Med       Date:  2012-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.